| 학회 |
한국고분자학회 |
| 학술대회 |
2012년 가을 (10/11 ~ 10/12, 창원컨벤션센터) |
| 권호 |
37권 2호 |
| 발표분야 |
Smart Carriers for Bioactive Molecules and Cells(의료용 고분자 부문위원회) |
| 제목 |
Development of a New Therapeutic Agent for Primay or Metastatic Hepatic Cancer |
| 초록 |
For treatment of hepatocellular carcinoma and metastatic hepatic cancer from mainly GI tract, a number of innovative liver-directed treatments have been developed, including hepatic arterial infusion chemotherapy (HAC), transarterial chemoembolization (TACE), and radioembolization (RE). Contrary that it is difficult to get the Yttrium-90 for SIRT, I-131 is the radioisotope that widely use to treat the patients with thyroid cancer after total thyroidectomy. My study focuses on the development of a new therapeutic agent using I-131 for selective internal radiochemotherapy (SIRCT). The agent been developing in my laboratory is a biodegradable and biocompatible hydrogel that has been modified with a chelator to label with I-131. |
| 저자 |
정환정 |
| 소속 |
전북대 |
| 키워드 |
hydrogel; selective internal radiotherapy; hepatic cancer
|
| E-Mail |
|
